Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
Sleep Well At Night With These 3 Buffett-Style Dividend Aristocrats
07:05am, Monday, 27'th Nov 2023
Even in today's overvalued market, Warren Buffett-style "wonderful companies at fair prices" are plentiful. That includes dividend aristocrats, the world's most dependable sources of steadily growing
3 Rising Stars: Invest Now in Tomorrow's Trillion-Dollar Companies
02:00pm, Sunday, 26'th Nov 2023
As the global economic landscape evolves, identifying burgeoning companies with potential to scale into trillion-dollar entities is a pursuit that captivates investors worldwide. In the realm of pharm
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
06:55am, Sunday, 26'th Nov 2023
AbbVie is a Dividend King with a bright future. Eli Lilly's dividend is just icing on the cake, with the company's growth prospects taking center stage.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
11:17am, Friday, 24'th Nov 2023
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Could AbbVie Stock Help You Become a Millionaire?
08:45am, Friday, 24'th Nov 2023
AbbVie has many drugs in its portfolio that can generate more than $1 billion each in annual revenue. The company generates strong free cash flow to support its dividend as well as growth opportunitie
How To Build A Dividend Portfolio Allocating $100,000 Among November's Top 20 Dividend Companies
06:00pm, Thursday, 23'rd Nov 2023
I will show you how you can build a dividend portfolio by allocating $100,000 among November's top 20 dividend companies as well as one ETF. I will conduct a deep risk analysis to demonstrate the redu
ABBV vs. LLY: Which Stock Should Value Investors Buy Now?
12:47pm, Tuesday, 21'st Nov 2023
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both AbbVie (ABBV) and Eli Lilly (LLY). But which of these two stocks offers value investors a better bang for th
AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks
11:53am, Tuesday, 21'st Nov 2023
Despite his reputation as a growth investor, Peter Lynch offers valuable insights into dividend stocks, too. These insights are often overlooked by many of us due to his success with high-growth stock
Dual Powerhouses: 7 Dividend Stocks Marrying High Yield With High Growth
07:54pm, Monday, 20'th Nov 2023
While it's always important to consider passive-income providers, they often lack an underlying growth impetus, which subsequently makes the concept of high-yield dividend growth stocks so compelling.
The Best 7 Dividend Stocks to Own in Retirement
08:04am, Sunday, 19'th Nov 2023
While getting to retirement age can be a blessing and a curse, the reality of counting on the U.S.
Up To 16% Dividend Growth And Yields Reaching 6%: November's Top 10 Dividend Growth Stocks
01:00pm, Saturday, 18'th Nov 2023
Dividend growth companies are an essential part of a risk-adjusted, well-balanced, and extensively diversified dividend income portfolio. I will present you with a list of 10 currently attractive divi
7 High-Yield Blue Chips Suitable for Any Retiree
03:23pm, Friday, 17'th Nov 2023
Before extolling the benefits of high-yield blue-chip stocks, it's important to acknowledge the reality that many investors are feeling. Long-term stock investors have had to muddle through challengin
AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?
05:00am, Thursday, 16'th Nov 2023
AbbVie's top-selling drug, Humira, has lost exclusivity, and its sales are falling. Pfizer is seeing lower demand for its blockbuster coronavirus vaccine.
7 Dividend Stocks Every Investor Should Own to Survive a Market Crash
12:41pm, Tuesday, 14'th Nov 2023
There are many ways to make money on Wall Street. One of the best proven strategies is buying and holding dividend stocks for long-term wealth creation.
Revealed: Congress' busiest stock traders in the last year
09:17am, Tuesday, 14'th Nov 2023
Over the past few weeks, Finbold has unveiled reports exposing the substantial stock market activities of certain US Congress members, some of which resulted in multimillion-dollar profits.
